logo

Novavax Inc. (NVAX)



Trade NVAX now with
  Date
  Headline
9/12/2022 9:29:13 AM Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Marketing Authorization In EU For Use As Booster For Adults
8/26/2022 9:30:12 AM Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization In U.K. For Use In Adolescents
8/18/2022 8:56:50 AM Novavax's Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval In New Zealand For Adolescents
8/17/2022 8:06:46 AM Novavax : New Zealand Grants Expanded Provisional Approval For Nuvaxovid COVID-19 Vaccine As First & Second Booster
8/15/2022 8:02:39 AM Novavax Submits Application To FDA For Emergency Use Authorization For COVID-19 Booster In Adults
8/12/2022 9:25:16 AM Novavax's Nuvaxovid COVID-19 Vaccine Approved In South Korea For Use In Adolescents Aged 12 Through 17
8/8/2022 4:09:59 PM Novavax Inc. (NVAX) Has Lowered Its 2022 Revenue Estimate To $2 - $2.3 Bln From $4 - $5 Bln
8/8/2022 4:06:53 PM Novavax Q2 Loss/share $6.53 Vs. Loss $4.75 Year Ago